Fadolmidine


Fadolmidine is an experimental α adrenergic receptor agonist that has been investigated as a spinal analgesic. It was developed with the aim of providing antinociceptive effects with reduced systemic side effects compared to other α agonists.

Pharmacology

Fadolmidine acts as a selective α adrenergic receptor agonist, a receptor class associated with modulation of nociceptive signalling. A 2004 review described preclinical evidence of spinal antinociceptive effects in laboratory models and suggested a reduced propensity for sedation compared with systemic α agonists.

Development

The compound was developed under the code MPV-2426. As of 2025, it has no approved medical indication and has not advanced to late-stage clinical development.

Chemistry

Fadolmidine is an imidazole-derived compound structurally related to other α agonists such as medetomidine and dexmedetomidine.